We present the involvement and association of TNF-related apoptosis-inducing ligand (TRAIL) with apoptosis. Its potential application as a therapeutic agent in urologic oncology is discussed. We have examined the sensitivity of prostate carcinoma cell lines DU145, PC3 and LNCaP to TRAIL-induced apoptosis and the expression of TRAIL receptors. Furthermore we looked into the sensitization of those prostate carcinoma cell lines to TRAIL-mediated apoptosis by low toxic levels of actinomycin-D. Furthermore, we review and discuss the pertinent literature on the molecular biology of TRAIL, its receptors and future potential for therapy in urologic oncology.
Introduction
Programmed cell death (apoptosis) helps in the elimination of unwanted cells, in contrast to necrosis which is not a physiological process. Apoptosis occurs during embryonal development and plays an important role in immunoregulation, tumor biology and tissue pathology. Cell death as a physiological pathway has been described and studied over 150 years, initially with the study of metamorphosis in amphibians. 1 The initial studies were based on the idea that the observed cell death occurred basically secondarily to tissue damage. The idea that cell death is a genetically controlled process in normal cells did not come until the late 1980s. Studies with the nematode Caenorhabditis elegans proved the theory that cell death was a genetically controlled pathway in normal cells, leading to new insights into the idea of programmed cell death. 2, 3 Distinct morphological features are noted in apoptotic cells like membrane blebbing, cellular shrinkage and condensation of chromatin which can be easily detected under the microscope. The biochemical processes leading to cell death by the apoptotic pathway is via the translocation of phosphatidylserine in the outer layer of cell membrane and the activation of endonuclease which cleaves genomic DNA into multiple internucleosomal fragments. In contrast, cell necrosis is based on noxious stimulants such as temperature, radiation, oxidation or trauma and not on genetically controlled pathways. On the cellular level necrosis is characterized by mitochondrial damage and cell lysis.
Defects in programmed cell death play a major role in the pathogenesis of tumors allowing neoplastic cells to survive beyond their normally intended lifespans. De®-ciencies in apoptosis also contribute to carcinogenesis by creating a permissive environment for genetic instability and accumulation of gene mutations. These mutations in turn permit dysregulation of cell cycle checkpoints which would normally induce apoptosis. Also these changes will facilitate growth factor and hormone independent cell survival, supporting anchorage independent survival during metastasis. 4 Therefore, strategies to interfere with the process of anti-apoptosis or to overcome its effects will be bene®cial in cancer therapy.
Recent discoveries of a new apoptosis-inducing molecule and its receptors has led to further broadening and insights into the apoptotic process. This molecule is part of the Tumor Necrosis Factor (TNF) superfamily and is called TNF-related apoptosis-inducing ligand (TRAIL) or APO2-L. This review discusses the biochemical characteristics and molecular biology of TRAIL and its receptors and their implication in cancer treatment.
TNF and TRAIL
TNF is a cytokine which plays an important role in acute and chronic in¯ammation and is also a mediator in endotoxic shock. It is mainly produced by T cells, natural killer cells (NK cells) and activate macrophages. It was ®rst discovered in the blood of BCG infected mice after they had been injected with endotoxin. 5 TNF has been shown to be cytotoxic for tumor cells in vitro and to cause hemorrhagic necrosis of tumors in mice. 6 ± 10 Since 1985 TNF has been available to medical oncology, but its systemic application in patients with advanced tumor diseases failed because of toxicities. The high systemic toxicities resulted in low maximal tolerated doses, rare tumor remissions and organ failure. 11, 12 Due to these problems clinical applications of TNF were limited though interest in its potential continued.
Between 1995 and 1996 two independent groups identi®ed and characterized a new membrane protein, 10, 13 whose amino acid sequence showed a 23% similarity to TNF-a and a 28% similarity to Fas-ligand (also known as Apo-1-ligand), which is a member of the TNF superfamily. 14 Thus, this new protein was grouped in the TNF superfamily and was called TRAIL or Apo-2-ligand, because of its similarity to Fas-ligand. TRAIL is a 281 amino acid protein with its C terminus exposed, indicating a type II transmembrane protein topology. The extracellular domaine of TRAIL is homologous to that of other family members. The discovery and subsequent cloning of TRAIL was based on bioinformatic analysis of expressed sequence tag (EST) databases which contain amino acid sequences of proteins that are expressed by the human genome, and whose function are undetermined. The characterization and subsequent cloning of TRAIL was based on the comparison of conserved TNF sequences with a particular EST database. 10, 13 
TRAIL and apoptosis
Based on the comparison of the crystalline structure of TNF it was initially suggested that TRAIL had its highest biological activity as a trimer. 15 Wiley et al proved this by showing that the soluble form of TRAIL, when multimeric or crosslinked, led to a higher induction of apoptosis when compared to the monomeric molecule. 10 These studies also revealed a very unique characteristic and quality of TRAIL in that it appeared to induce apoptosis only in tumorigenic or transformed cells but not in normal cells in vitro. Moreover, TRAIL is expressed by a wide range of tissues like lymphocytes, spleen, prostate, ovary, colon and placenta, whereas TNF expression is more restricted and only transient in activated cells. 10 Because of the discovery of different tissues expressing TRAIL it was suggested that the regulation of TRAILinduced apoptosis was controlled by a restrictive expression of a single TRAIL receptor.
TRAIL and its receptors
The ®rst TRAIL receptor was identi®ed and cloned again with the help of an EST database in 1997 and was called TRAIL-R1. 16 This protein showed several identical characteristics to the receptors of the TNF-superfamily and was thus also called death receptor 4 (DR4) (in continua- Figure 1 Schematic representation of the four TRAIL receptors. The two extracellular boxes represent the cysteine rich pseudorepeats. 50 
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A van Ophoven et al tion of previously discovered TNF-DR1-3). TRAIL-R1 is a type I membrane protein with two extracellular cysteine rich pseudorepeats. Its cytoplasmatic part is made up of a death domain (DD) which signals and induces apoptosis ( Figure 1 ). Again, the DD of TRAIL-R1 also shows a high similarity to the known death domain of the TNF receptors. Shortly after the discovery of TRAIL-R1, a second receptor, TRAIL-R2 or DR5 was identi®ed. 17 ± 19 Its amino acid sequence shows a 58% similarity to TRAIL-R1 and is a type I transmembrane protein with two extracellular cysteine pseudorepeats and a cytoplasmic DD. Since most tissues express both TRAIL-R1 and -R2 it has become apparent that the ligand and receptor system of TRAIL is far more complex than ®rst anticipated, leaving the reason for the tumor selectivity of TRAIL unclear at that time.
The complexity of the TRAIL system grew with the discovery of two further receptors, but this knowledge also led to the information about cell sensitivity and resistance to TRAIL. 17,18,20 ± 22 The two receptors TRAIL-R3 and R4 showed a 58% and 54%, 58% and 57% similarity to TRAIL-R1 and -R2, respectively, as well as a 70% similarity between themselves. However, the importance of the R3 and R4 lies not in the similarities to R1 and R2, but in their differences. In contrast to R1 and R2, R3 contains neither an intracellular DD nor a transmembranous domain, and is glycosylphosphatidylinositol (GPI)-anchored to the cell surface. R4 differs in that in only has a truncated DD and does not signal for apoptosis. However, the four receptors are capable of binding TRAIL with comparable binding af®nity. Thus TRAIL-R3 and R4 can compete with TRAIL-R1 and R2 for the TRAIL molecule without inducing apoptosis. The genes of the four TRAIL receptors are tightly clustered on human chromosome 8p21-22 suggesting that they evolved recently via gene duplication. 20 ± 22 The expression of TRAIL-R4 in various tissues is almost comparable to TRAIL-R1 and R2, while that of TRAIL-R3 is more limited. 17, 18, 20 TRAIL sensitivity and resistance
The discovery of expression of TRAIL and its receptors in normal cells led to doubts in the theory that regulation of TRAIL-induced apoptosis was controlled by restrictive expression of receptors. The possibility of regulation by different receptor af®nity was also excluded because all the receptors showed comparable binding af®nities. 20, 21 The ®rst hypothesis of TRAIL sensitivity and resistance was based on the receptors R3 and R4 being devoid of functioning DD and that these receptors act as decoy receptors (DcR) by binding to TRAIL but not inducing apoptosis. This theory was supported by the fact that (a) the CdRs were almost exclusively found in normal healthy cells and (b) by transfection studies using TRAIL sensitive tumor cell lines. After transfection with either TRAIL-R3/DcR1 or TRAIL R4/DcR2 a decrease of apoptotic cell death was observed with greater effect seen in DcR2 transfection. 21 Although this theory was intriguing, the discover of TRAIL sensitive tumor cell lines expressing DcRs and TRAIL resistant tumor cell lines without DcRs implied a more extensive and complicated pathway.
Moreover, recent screening experiments of more than 60 human tumor cell lines showed no de®nitive correlation between the mRNA expression of the different TRAIL receptors and TRAIL sensitivity. 23 Though mRNA expression does not necessarily imply cell surface expression, studies with monoclonal antibodies speci®c for TRAIL receptors supported the PCR data. 23 An alternative hypothesis for the explanation of different TRAIL sensitivity of tumor cells and normal cells was based on TRAIL-R4's ability to induce intracellular antiapoptotic signals. Activation of nuclear factor kappa B (NF-kB) protects cells from TNF-induced cell death probably due to upregulation of one or more genes resulting in cell resistance to apoptosis. 24, 25 Binding of TRAIL-R4 leads to NF-kB activation and thus a possible reason for TRAIL resistance. 21 On the other hand TRAIL-R1 and R2 have been shown to activate NF-kB without any antiapoptotic effect. 26, 27 thus suggesting that the TRAIL sensitivity and resistance is not solely based on TRAIL-R4 and NF-kB.
The most complex theory is based on the interaction of different activators and inhibitors of cell death machinery. Initial studies of TRAIL-induced apoptotic pathways focused on the possible similarities to TNF and Fas death receptor pathways. These pathways involve the binding of Fas-associated-DD (FADD) proteins either directly (FADD mediated) or indirectly (TNF-R1-associated-DD (TRADD) mediated) leading to activation of apoptotic cell death (Figure 2 ). Binding to either of these adaptor molecules leads to activation of the caspasecascade resulting in apoptopic cell death. 28 ± 30 Caspases, which constitute the key effector molecules for apoptotic pathways, are synthesized as inactive cysteine proteases comprising an N-terminal peptide together with one large and one small subunit. Actiavtion of caspases by proteolytic cleavage results in the cleavage of critical cellular substrates, precipitating the morphological changes of apoptosis. 31 The exact mechanism of TRAIL-mediated cell death in association with FADD/TRADD continues to remain unclear because of contradictory data involving the binding of the adaptor molecules to TRAIL-R1 and R2. In-vitro studies have shown both, no binding of FADD/TRADD to TRAIL receptor 16 ± 18 as well as binding. 26, 27 The discrepancy between the two study results may be due to different expression levels of the adaptor molecules in the transfectans used in the experiments. Even though early data appears con¯icting, the theory of activation of caspase-cascade via FADD or TRADD by TRAIL still provides the most promising explanation for TRAIL-induced apoptosis. Further support for this theory has been shown indirectly by in-vitro studies blocking caspase inhibitors and resulting in an increased TRAIL sensitivity. 32 However the possibility of more extracellular and intracellular factors involved in cell apoptosis still exists. 33 
TRAIL and p53
Tumor suppression is known to be partly in control of the p53 gene which regulates cell cycle and apoptosis. In the event of chromosomal damage p53 inhibits further cell replication and induces cell death. The exact mechanism of cell death induction is still unclear. 34, 35 The TRAIL and TNF superfamily apoptotic pathways were initially thought to be independent of p53. However, recent studies have shown an association of p53 to the Fas-ligand 36 and more recently its relationship to the TRAIL receptor. 37, 38 The studies cloned a p53-dependent gene which was induced by DNA damage called KILLER gene. This KILLER gene was identical to the TRAIL-R2 gene. The KILLER/TRAIL-R2 gene was highly expressed in DNA damaged cells when overexpression of a wildtype P53 transgene occurred. Tumor cells with P53 mutations did not show expression of the KILLER gene. This led to the conclusion that P53 is involved in the TRAIL receptor and caspase apoptotic cell death pathway. The involvement of p53 gene leads to further questions such as the in¯uence of p53 on TRAIL-R2 expression and the role of p53/TRAIL-interaction in apoptotic regulation.
Therapeutic potentials of TRAIL
Based on the in-vitro studies, Walczak et al have conducted the ®rst in-vivo study using TRAIL. The study looked at the toxicity and ef®cacy of TRAIL in SCID mice 
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A van Ophoven et al injected with mammary cancer MDA-231. After intravenous injection of 500 mg human TRAIL and 1 mg murine TRAIL no signi®cant toxicity was seen with mice viability, tissue integrity and blood count.
When TRAIL was given to mice with either subcutaneous or intraperitoneal (ip) tumors a signi®cant longer survival was noted in mice with ip administered TRAIL as compared to control (69 days vs 35.5 days). The effect of tumor regression was noted to be dose-dependent and when the mice with subcutaneous MDA-231 tumors were given 500 mg of TRAIL for ten days, iv or ip, the tumor was undetectable in 80% and 100% of the mice, respectively, after 40 days. Similar results were obtained with two human colon carcinomas, COLO-205 and HCT-15. 39 The authors showed that the effect of TRAIL was based on immediate apoptosis in all three malignancies.
We have recently reported studies performed in vitro on the sensitivity of AIDS-Kaposi's sarcoma to TRAILmediated apoptosis. AIDS-KS are resistant to killing by chemotherapeutic drugs and cytotoxic effector lymphocytes. The acquisition of anti-apoptotic characteristics by AIDS-KS cells may contribute to their prolonged survival. Receptor expression was determined by RT-PCR. The level of the receptor mRNA expression was compared to the mRNA level of GAPDH. ( 7 0 ± 5% of GAPDH; , 5 ± 25% of GAPDH; , 25 ± 50% of GAPDH; , 50 ± 75% of GAPDH; , 75 ± 100% of GAPDH). b Resistant indicates`5.0% killing at 500 ng/ml TRAIL. Figure 3 Sensitization of prostate carcinoma cell lines DU145, PC3 and LNCaP to TRAIL-mediated apoptosis by low toxic levels of actinomycin-D (ActD). The cells were treated in 0, 10, 50, 100 ng/ml ActD in combination with or without TRAIL (50 ng/ml) for 24 hours. The cells were subsequently stained with propidium iodide (50 mg/ml) and sub-G1 (apoptotic) fraction was determined by one-color cell cycle¯ow cytometric analysis. (r, untreated; d, treated with 50 ng/ml TRAIL).
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We examined the sensitivity of ten different isolates of AIDS-KS to TRAIL-mediated apoptosis and found they were all relatively resistant. However, combination of TRAIL and actinomycin-D (ActD) resulted in a synergistic cytotoxic activity in nine of the ten samples. We also demonstrated the involvement of BCL-XL selectively in the sensitization of AIDS-KS to TRAIL-induced apoptosis. 40 These ®ndings suggest that the combination of TRAIL and ActD may be a potential option in the treatment of AIDS-KS.
TRAIL and prostate cancer
We have also recently examined the sensitivity of prostate carcinoma cell lines to TRAIL-induced apoptosis and the expression of TRAIL receptors by RT-PCR. Table 1 summarizes the expression of TRAIL receptors on PC3, DU145 and LNCaP cells. All three cell lines express the four receptors at different levels. Furthermore, all three cell lines were resistant to TRAIL-mediated apoptosis. However, when the cells were treated with ActD they became sensitized to apoptosis (Figure 3 ). These results suggest that the combination of TRAIL and ActD may be a therapeutic option in the treatment of drug/hormone refractory prostate carcinoma. (Ng et al, in preparation).
Conclusions
The impressive in-vivo and in-vitro results open new therapeutic options for cancer. The therapeutic option of directly inducing the cell death pathway via the TRAIL receptors has many implications and provides a promising future in antitumor therapy. A p53-independent induction of apoptosis is a promising therapeutic approach, because of the high amount of human tumors with p53 mutations. Moreover, targeting of death receptors for tumor therapy is attractive, because of their p53-independent induction of the caspase-cascade. Recent in-vitro studies showed a caspase-associated apoptosisinduction in several prostate and renal cell carcinoma. 41 ± 44 Several chemotherapeutics aim at DNA damage resulting in subsequent p53-induction. Others, particularly anthracyclines, have been demonstrated to activate caspases through a variety of mechanisms. 45, 46 The combination of those chemotherapeutics with TRAIL may increase the anti-proliferative effect of the single drug via synergy or activation of additional apoptotic signaling. Recent invitro data showed a signi®cant increase of apoptotic cell death rate following the combined application of TRAIL with doxorubicin, 5-¯uoruracil, 47 adriamycin, taxol or etoposide. 48 The augmentation of caspase activation observed may be due to its ampli®cation upon reception of two independent activating signals. However, the exact mechanism is not yet known. TRAIL may also be used in combination therapy with other immunotherapies or gene therapies providing a synergistic effect or enhancing the ef®cacy of another therapeutic regimen. Moreover, it can be used as monotherapy for treatment of tumors either systemically or by direct intratumoral application in the absence of toxicity. The discovery of TRAIL as part of the TNF superfamily and its impressive results again opens the door for the study of the role of TNF and its superfamily in cells and will provide further knowledge of cell and tumor biology.
